Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 90 EV-to-EBITDA is 8.43 as of Aug. 05, 2026, which is 43% below its 10-year median of 14.72. GuruFocus rates KYKOF with a GF Score™ of 90/100 and a GF Value™ of $16.44. The stock has 1 warning sign investors should review. Among 745 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 69.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kyowa Kirin Co's enterprise value is $6,764 Mil.
Kyowa Kirin Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $803 Mil. Therefore, Kyowa Kirin Co's EV-to-EBITDA for today is 8.43.
The historical rank and industry rank for Kyowa Kirin Co's EV-to-EBITDA or its related term are showing as below:
KYKOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.08 Med: 14.72 Max: 26.86
Current: 9.19
During the past 13 years, the highest EV-to-EBITDA of Kyowa Kirin Co was 26.86. The lowest was 7.08. And the median was 14.72.
KYKOF's EV-to-EBITDA is ranked better than 69.4% of 745
companies
in the Drug Manufacturers industry
Industry Median: 13.04
vs KYKOF: 9.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kyowa Kirin Co (OTCPK:KYKOF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kyowa Kirin Co's PE Ratio (TTM) for today is calculated as:
Kyowa Kirin Co's share price for today is $14.425.
Kyowa Kirin Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.911.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Kyowa Kirin Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's EV-to-EBITDA falls into.
Kyowa Kirin Co's current Enterprise Value is $6,764 Mil.
Kyowa Kirin Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $803 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a EV-to-EBITDA of 8.43 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kyowa Kirin Co. This is 43% below median its historical median of 14.72. Over the past decade, Kyowa Kirin Co's EV-to-EBITDA has ranged from 7.08 to 26.86. According to the industry distribution chart, Kyowa Kirin Co ranks #228 out of 745 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Kyowa Kirin Co's EV-to-EBITDA too high?
Kyowa Kirin Co's current EV-to-EBITDA of 8.43 is 43% below median its 10-year median of 14.72. Over the past 10 years, this metric has ranged from a low of 7.08 to a high of 26.86. The Drug Manufacturers industry median EV-to-EBITDA is 13.04. Kyowa Kirin Co's value of 8.43 is 35.4% below this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #228 out of 745 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #228 out of 745 companies for EV-to-EBITDA. This puts Kyowa Kirin Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.04. Kyowa Kirin Co's value of 8.43 is 35.4% below this benchmark. Historically, Kyowa Kirin Co's own EV-to-EBITDA has ranged from 7.08 to 26.86 over the past decade. While the company's 10-year median is 14.72 vs. the industry median of 13.04, Kyowa Kirin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.04, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current EV-to-EBITDA of 8.43 is 35.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kyowa Kirin Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current EV-to-EBITDA is 8.43, which is 43% below median its own 10-year median of 14.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Kyowa Kirin Co (KYKOF) has a current EV-to-EBITDA of 8.43. The stock's GF Value™ is $16.44, compared to a current price of $14.43 — trading 12.3% below its estimated fair value. The current EV-to-EBITDA is 8.43, which is 43% below median its 10-year median of 14.72 and 35.4% below the Drug Manufacturers industry median of 13.04. Kyowa Kirin Co's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current EV-to-EBITDA is 8.43 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 12.3% below its estimated GF Value™ of $16.44.
Key valuation signals for KYKOF:
EV-to-EBITDA: 8.43 (43% below median its 10-year median of 14.72)
GF Value™: $16.44 vs. price of $14.43 (12.3% below fair value)
Industry Position: 35.4% below the Drug Manufacturers median (#228 of 745)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
90GF Score
Get the complete analysis for KYKOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
